# OnCo record paper-archer-1050-os-jco-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-archer-1050-os-jco-2018" ;
  schema:name "Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations"@en ;
  schema:description "The mature survival analysis of ARCHER 1050: patients on dacomitinib lived a median of 34.1 months against 26.8 months on gefitinib, the first survival gain for a second-generation EGFR inhibitor over a standard one."@en ;
  schema:url <https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2018.78.7994>, <https://pubmed.ncbi.nlm.nih.gov/29864379/>, <https://clinicaltrials.gov/study/NCT01774721> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2018.78.7994> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Mok TS, Cheng Y, Zhou X, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/gefitinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct01774721/> ;
  onco:people <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/wu-yi-long/> ;
  onco:journals <https://onco.cc/journals/jco/> .